MX2014009015A - Stable amorphous raltegravir potassium premix and process for the preparation thereof. - Google Patents
Stable amorphous raltegravir potassium premix and process for the preparation thereof.Info
- Publication number
- MX2014009015A MX2014009015A MX2014009015A MX2014009015A MX2014009015A MX 2014009015 A MX2014009015 A MX 2014009015A MX 2014009015 A MX2014009015 A MX 2014009015A MX 2014009015 A MX2014009015 A MX 2014009015A MX 2014009015 A MX2014009015 A MX 2014009015A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- stable amorphous
- raltegravir potassium
- amorphous raltegravir
- potassium premix
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a stable amorphous Raltegravir potassium premix, method of making and pharmaceutical composition thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN72KO2012 | 2012-01-25 | ||
PCT/IB2013/050643 WO2013111100A1 (en) | 2012-01-25 | 2013-01-25 | Stable amorphous raltegravir potassium premix and process for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014009015A true MX2014009015A (en) | 2014-12-08 |
Family
ID=47754907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014009015A MX2014009015A (en) | 2012-01-25 | 2013-01-25 | Stable amorphous raltegravir potassium premix and process for the preparation thereof. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20150328215A1 (en) |
EP (1) | EP2806857A1 (en) |
JP (1) | JP2015504913A (en) |
KR (1) | KR20140114406A (en) |
CN (1) | CN104093400A (en) |
AU (1) | AU2013213255A1 (en) |
BR (1) | BR112014018247A8 (en) |
CA (1) | CA2863575A1 (en) |
MX (1) | MX2014009015A (en) |
RU (1) | RU2014134257A (en) |
WO (1) | WO2013111100A1 (en) |
ZA (1) | ZA201405247B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015140765A1 (en) * | 2014-03-21 | 2015-09-24 | Mylan Laboratories Ltd. | A premix of crystalline raltegravir potassium salt and a process for the preparation thereof |
CN104146949A (en) * | 2014-08-29 | 2014-11-19 | 宁夏泰瑞制药股份有限公司 | Premixing agent for tiamulin fumarate, and preparation method thereof |
TWI790189B (en) | 2015-01-02 | 2023-01-21 | 美商梅拉洛伊卡公司 | Bacterial compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL161337A0 (en) | 2001-10-26 | 2004-09-27 | Angeletti P Ist Richerche Bio | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
UA87884C2 (en) | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Potassium salt of an hiv integrase inhibitor |
CN101161244A (en) * | 2006-10-13 | 2008-04-16 | 上海世康特制药有限公司 | Nimodipine tablet and its preparing method |
WO2010140156A2 (en) | 2009-06-02 | 2010-12-09 | Hetero Research Foundation | Novel polymorphs of raltegravir potassium |
WO2010143207A1 (en) * | 2009-06-11 | 2010-12-16 | Rubicon Research Private Limited | Taste-masked oral formulations of influenza antivirals |
WO2011024192A2 (en) * | 2009-07-27 | 2011-03-03 | Matrix Laboratories Ltd | Novel polymorphs of raltegravir |
SI2796458T1 (en) * | 2010-04-01 | 2018-04-30 | Teva Pharmaceutical Industries Ltd. | Crystalline raltegravir sodium salts |
US8962833B2 (en) * | 2010-05-25 | 2015-02-24 | Hetero Research Foundation | Salts of raltegravir |
-
2013
- 2013-01-25 RU RU2014134257A patent/RU2014134257A/en not_active Application Discontinuation
- 2013-01-25 CA CA2863575A patent/CA2863575A1/en not_active Abandoned
- 2013-01-25 MX MX2014009015A patent/MX2014009015A/en unknown
- 2013-01-25 JP JP2014553843A patent/JP2015504913A/en active Pending
- 2013-01-25 EP EP13706739.3A patent/EP2806857A1/en not_active Withdrawn
- 2013-01-25 US US14/373,940 patent/US20150328215A1/en not_active Abandoned
- 2013-01-25 KR KR1020147021494A patent/KR20140114406A/en not_active Application Discontinuation
- 2013-01-25 WO PCT/IB2013/050643 patent/WO2013111100A1/en active Application Filing
- 2013-01-25 BR BR112014018247A patent/BR112014018247A8/en not_active IP Right Cessation
- 2013-01-25 AU AU2013213255A patent/AU2013213255A1/en not_active Abandoned
- 2013-01-25 CN CN201380006517.5A patent/CN104093400A/en active Pending
-
2014
- 2014-07-17 ZA ZA2014/05247A patent/ZA201405247B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20150328215A1 (en) | 2015-11-19 |
RU2014134257A (en) | 2016-03-20 |
BR112014018247A2 (en) | 2017-06-20 |
ZA201405247B (en) | 2015-12-23 |
KR20140114406A (en) | 2014-09-26 |
EP2806857A1 (en) | 2014-12-03 |
BR112014018247A8 (en) | 2017-07-11 |
JP2015504913A (en) | 2015-02-16 |
CA2863575A1 (en) | 2013-08-01 |
WO2013111100A1 (en) | 2013-08-01 |
AU2013213255A9 (en) | 2016-06-16 |
AU2013213255A1 (en) | 2014-08-07 |
WO2013111100A9 (en) | 2014-08-14 |
CN104093400A (en) | 2014-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012156998A3 (en) | Amorphous mirabegron and processes for crystal forms of mirabegron | |
MD20150091A2 (en) | Anti-viral compounds | |
IN2015KN00262A (en) | ||
MX2011008262A (en) | Substituted spiro-amides as b1r modulators. | |
EA033455B1 (en) | Crystalline forms of substituted 5-fluoro-1h-pyrazolopyridines, processes for preparing same, use thereof for producing a medicament, medicament and method of treatment based thereof | |
IN2015KN00323A (en) | ||
MX370649B (en) | Process for the preparation of teneligliptin. | |
MX2015005891A (en) | Polymorphic forms of suvoroxant. | |
MY195343A (en) | A Novel Phtalazinone Derivatives and Manufacturing Process Thereof | |
MX2014010433A (en) | Novel crystalline form of sitagliptin sulfate. | |
UA116889C2 (en) | COMPOSITION COMPRISING A MIXTURE OF CD95-Fc ISOFORMS | |
WO2014203275A3 (en) | An improved process for the preparation of apixaban and intermediates thereof | |
MX2016008369A (en) | Pharmaceutical composition containing palonosetron. | |
WO2013164839A3 (en) | Amorphous form of apixaban, process of preparation and compositions thereof | |
MX2017001487A (en) | Sofosbuvir in crystalline form and process for its preparation. | |
WO2012131707A3 (en) | Crystalline form of bortezomib, preparation method and pharmaceutical composition there f | |
WO2014068586A3 (en) | Solid oral compositions of tolvaptan | |
EP2700322A4 (en) | Composition containing scirpusin b, and process for producing composition containing scirpusin b | |
MX2015003034A (en) | Syringe containing a composition, especially a pharmaceutical composition, comprising immunoglobins, method for the production thereof and use of same. | |
EP2742946A4 (en) | Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof | |
MX2014009015A (en) | Stable amorphous raltegravir potassium premix and process for the preparation thereof. | |
MX2012010443A (en) | Process for the preparation of 5-substituted 1-alkyltetrazoles. | |
MX2012010317A (en) | β-hydroxyalkylamides, method for their production and use thereof. | |
IN2014DN09451A (en) | ||
EP2575465A4 (en) | Salts of raltegravir |